Viatris pays 9.3 times Pacira's EBITDA to build a non-opioid pain line before its own FDA ruling

Measured against Pacira's trailing year, Viatris is paying about 2.2 times revenue and 9.3 times adjusted EBITDA ^[16][17]. Put the other way, the $177 million of adjusted EBITDA Pacira earned in the twelve months to June 30 ^[8] is a yield of roughly 10.7% on the purchase price ^[18], before any cost savings. Both multiples use the $1.65 billion headline ^[2], with no adjustment for Pacira's own debt or cash.

At that yield the accretion claim is easy to meet. Viatris says the deal will be immediately accretive to its guidance metrics ^[3]. It is paying mainly with cash on hand and covering the rest with short-term borrowing ^[9].

Viatris also projects little effect on its gross leverage ratio ^[9]. Gross leverage counts debt and ignores cash. A cash-funded deal therefore leaves the debt side about where it was while Pacira's EBITDA joins the earnings side. Net debt still rises by every dollar that leaves. A Seeking Alpha contributor credits Viatris with improving cash flow, reducing leverage and keeping up shareholder returns despite declining legacy brands, high debt and restructuring ^[13]. The $1.65 billion going to Pacira holders is cash that will not go to debt repayment or buybacks.

Stalled growth is the harder test, and the contributor presents the deal as a response to revenue stagnation ^[1]. The same writer, who discloses a long position in Viatris ^[15], upgrades the stock only from Sell to Hold and warns that execution risks and legacy revenue declines persist ^[14]. Neither source gives Viatris's own revenue, so this record cannot show how much of that decline Pacira's $746 million ^[8] would offset. The growth case rests on two things. One is Viatris using its global infrastructure to sell more of Pacira's patent-protected products ^[4]. The other is a drug the FDA has not yet cleared.

Scott A. Smith, Viatris's chief executive, said Exparel and Zilretta "are synergistic with our fast-acting meloxicam market opportunity and position us as a leader in non-opioid pain management therapies" ^[10]. The FDA's decision deadline on that meloxicam formulation is Dec. 27, according to the Wall Street Journal ^[11]. The Pacira deal is expected to close by the end of 2026 ^[6].

If the FDA approves it, Viatris has three non-opioid pain products to sell side by side. A rejection or delay leaves it holding $177 million of EBITDA bought at 9.3 times ^[17], still accretive, with Exparel and Zilretta ^[7] carrying the growth case alone. In either case, if the legacy decline is large next to $746 million, earnings improve while total revenue stays flat. I think the price is fair for what Viatris is buying and the growth claim is unproven. The Seeking Alpha contributor makes the counter-case, calling the deal a strategic step for a company that has already improved cash flow and cut leverage ^[14][13]. Pacira kept about 24% of its revenue as adjusted EBITDA ^[19], so the higher margins the contributor describes ^[4] depend on Viatris running those products through its own infrastructure. I would be wrong if Pacira's revenue runs well past $746 million in its first full year inside Viatris, or if Viatris reports total revenue growth after the close.

Traders have mostly priced in the close. Pacira rose about 44% premarket against a 45% offer premium ^[12][5]. On Wednesday's $25.20 close that implies about $36.29, within roughly 0.6% of the $36.50 offer ^[21]. Viatris shares slipped about 0.1% ^[12] on a deal that pays Pacira holders roughly $510 million above their Wednesday market value ^[20].